Shares of MannKind Corp. (NASDAQ:MNKD) fall as much as 27.105% prior to Tuesday’s Endocrinologic and Metabolic Drugs Advisory Committee Meeting. MannKind Corporation (NASDAQ:MNKD) stock performance was -16.77% in last session and finished the day at $4.02. Traded volume was 30,207,668 million shares in the last session and the average volume of the stock remained 7.92 million shares. The beta of the stock remained 1.47. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) on Mar. 31 released the top line results of the 12-month Phase II Imaging trial in Alzheimer’s Disease (“IMAGINE” Trial), based on draft results. Prana’s PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR). Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) dropped -71.60 percent to $2.80 yesterday on volume of 23.73 million shares. The intra-day range of the stock was $2.78 to $3.24. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has a market capitalization of $116.61 million.
Oi SA (ADR) (NYSE:OIBR) in accordance with article 157, paragraph 4 of Law No. 6,404/76 and CVM Instruction No. 358/02, and in furtherance of the Material Facts dated as of October 2, 2013 and February 20, 2014, notifies its shareholders and the market in general that as of the date hereof, Oi became aware of the decision issued by the Collegiate of the Brazilian Securities and Exchange Commission (“CVM”) regarding the appeal filed by Oi in connection with (i) the exercise of voting rights in relation to the agenda of the general shareholders’ meeting called for March 27, 2014 regarding the valuation report of assets to be contributed by Portugal Telecom SGPS, S.A. Oi SA (ADR) (NYSE:OIBR)’s stock on Mar 31, 2014 reported a decrease of -5.67% to the closing price of $1.33. Its fifty two weeks range is $1.32 -$3.12. The total market capitalization recorded $ 2.18 billion. The overall volume in the last trading session was 9,123,593 million shares. In its share capital, Oi SA (ADR) (NYSE:OIBR) has 1.64 million outstanding shares.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Mar. 28 announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. On Monday, shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) dropped -10.72% to close the day at $4.08. Company’s monthly performance is recorded as -29.53%. Idera Pharmaceuticals Inc (NASDAQ:IDRA) quarterly revenue growth is 20.00%.